5-methyl-2-(4-(trifluoromethyl)phenyl)oxazole | 1393588-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-2-(4-(trifluoromethyl)phenyl)oxazole
• 英文别名: 5-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole
• CAS: 1393588-56-1
• 化学式: C₁₁H₈F₃NO
• 分子量: 227.186
• InChiKey: GUTKNPBDYMSOLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-methyl-2-(4-(trifluoromethyl)phenyl)oxazole 、 (4-methylpent-4-en-1-yn-1-yl)benzene 在 manganese(IV) oxide 、 Cp*Rh(CH₃CN)₃(SbF₆)₂ 、 苯氧乙酸 作用下， 以 甲苯 为溶剂， 反应 51.0h， 以64%的产率得到2-(2,6-bis((E)-4-methyl-1-phenylpenta-1,4-dien-2-yl)-4-(trifluoromethyl)phenyl)-5-methyloxazole
  参考文献：
  名称：

  Rh(III)-催化烯化从功能性炔烃构建多种恶唑衍生物

  摘要：

  通过直接使用恶唑作为导向基团，实现了一种新颖的Rh( III )催化恶唑烯化反应生成多种恶唑骨架衍生物。该反应可以耐受许多官能团，以中等至良好的产率提供具有长链烯基的复杂恶唑衍生物，这可能在构建多种化合物中得到应用。

  DOI：

  10.1039/d1ob00507c
• 作为产物：
  描述：

  N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 生成 5-methyl-2-(4-(trifluoromethyl)phenyl)oxazole
  参考文献：
  名称：

  高选择性构建氮杂稠合吡咯并异喹啉衍生物

  摘要：

  报道了一种新型 Rh(III) 催化的级联 C−H 活化/环化/亲核攻击/2-苯基恶唑与马来酰亚胺的迈克尔加成，用于通过条件控制高选择性地构建吡咯并异喹啉衍生物。在该反应中，恶唑被用作导向基团和潜在的功能化试剂，H 2 O 是亲核试剂。该协议的显着特点包括原子经济性和高度区域选择性。

  DOI：

  10.1002/ejoc.202201267

文献信息

• Rh(<scp>iii</scp>)-Catalyzed three-component cascade annulation to produce the <i>N</i>-oxopropyl chain of isoquinolone derivatives
  作者：Yuan He、Xian-Zhang Liao、Lin Dong、Fen-Er Chen

  DOI：10.1039/d0ob02389b

  日期：——

  versatile functional groups at the N-substituents of isoquinolone scaffolds is still a great challenge. Herein, we report a novel three-component cascade annulation reaction to efficiently construct the N-oxopropyl chain of isoquinolone derivatives via rhodium(III)-catalyzed C–H activation/cyclization/nucleophilic attack, with oxazoles used both as the directing group and potential functionalized reagents

  开发强大的方法以在异喹诺酮支架的N-取代基处引入多功能官能团仍然是一个巨大的挑战。在本文中，我们报道了一种新颖的三组分级联环化反应，可通过铑（III）催化的CH-H活化/环化/亲核攻击有效地构建异喹诺酮衍生物的N-氧丙基链，恶唑同时用作指导基团和潜在基团。功能化试剂。
• Organic compounds
  申请人：Damon Edson Robert

  公开号：US20070004704A1

  公开（公告）日：2007-01-04

  Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

  本发明的化合物具有以下公式，可提供与过氧化物酶体增殖物激活受体（PPARs）结合的药理剂。因此，本发明的化合物对于治疗哺乳动物中由PPAR受体活性介导的疾病是有用的。这些疾病包括失调脂质代谢、高脂血症、高胆固醇血症、动脉粥样硬化、高甘油三酯血症、心力衰竭、心肌梗死、血管疾病、心血管疾病、高血压、肥胖症、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼部疾病、炎症性肠病（IBD）、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物中作为降糖药物特别有用，用于治疗和预防因受损葡萄糖耐受性、高血糖和胰岛素抵抗而引起的疾病，例如1型和2型糖尿病以及X综合症。
• Derivative having ppar agonistic activity
  申请人：Itai Akiko

  公开号：US20090286974A1

  公开（公告）日：2009-11-19

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.

  化合物的公式（I）：其药物可接受的盐或溶剂，其中环Q是可选择的取代的单环芳基，可选择的取代的单环杂芳基，可选择的融合芳基或可选择的融合杂芳基，Y1是键或-NR6-或类似物，环A是可选择的取代的非芳香杂环二基，公式组：-Y2Z1-是公式组：R7各自独立地是氢，可选择的取代的低烷基或类似物，R8和R9各自独立地是氢或可选择的取代的低烷基，n是1到3之间的整数，Z1是键，-O-，-S-或-NR9-，环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基，Y3是键，可选择的取代的低烷基，可选择地介入-O-，可选择的取代的低烯基或类似物，并且Z2是COOR3或类似物。
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Bach Andrew Thomas

  公开号：US20090118160A1

  公开（公告）日：2009-05-07

  Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARα and PPARγ receptors.

  该公式化合物提供了药理剂，它们是过氧化物酶体增殖物激活受体（PPARs）的有效激动剂。因此，本发明的化合物对于治疗哺乳动物PPAR受体活性介导的疾病非常有用。这些疾病包括血脂异常、高脂血症、高胆固醇血症、动脉粥样硬化、高三酰甘油血症、心力衰竭、心肌梗死、血管疾病、心血管疾病、高血压、肥胖症、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼科疾病、炎性肠病、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物中作为降血糖药物特别有用，用于治疗和预防因受损的葡萄糖耐受性、高血糖和胰岛素抵抗而引起的疾病，例如1型和2型糖尿病以及X综合症。本发明的化合物中特别优选PPARα和PPARγ双重激动剂。
• DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1939189A1

  公开（公告）日：2008-07-02

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y1 is a bond or -NR6- or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y2 Z1- is a group of the formula: or R7 are each independently hydrogen, optionally substituted lower alkyl or the like, R8 and R9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z1 is a bond, -O-, -S- or -NR9-, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y3 is a bond, optionally substituted lower alkylene optionally intervened by -O-, optionally substituted lower alkenylene or the like, and Z2 is COOR3 or the like.

  式 (I) 的化合物： 其药学上可接受的盐或溶液，其中 环 Q 是任选取代的单环芳基、任选取代的单环杂芳基、任选取代的融合芳基或任选取代的融合杂芳基、 Y1 是键或 -NR6- 或类似物、 环 A 是任选取代的非芳杂环二基、 式中的基团：-Y2 Z1- 是式中的基团： 或 R7 各自独立地为氢、任选取代的低级烷基或类似物、 R8 和 R9 各自独立地为氢或任选取代的低级烷基、 n 是介于 1 和 3 之间的整数、 Z1 是键、-O-、-S- 或 -NR9-、 环 B 是任选取代的芳香碳环基或任选取代的芳香杂环基、 Y3 是键、任选被-O-、任选被-S-或-NR9-取代的低级亚烷基、任选被取代的低级烯基或类似物，以及 Z2 是 COOR3 或类似物。